BIOTEST AG (BIO.DE) Stock Fundamental Analysis
FRA:BIO - Deutsche Boerse Ag - DE0005227201 - Common Stock - Currency: EUR
We assign a fundamental rating of 5 out of 10 to BIO. BIO was compared to 72 industry peers in the Biotechnology industry. BIO has an average financial health and profitability rating. BIO has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year BIO was profitable.
BIO had a positive operating cash flow in the past year.
In the past 5 years BIO reported 4 times negative net income.
BIO had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
BIO's Return On Assets of 13.97% is amongst the best of the industry. BIO outperforms 97.22% of its industry peers.
BIO has a better Return On Equity (35.86%) than 94.44% of its industry peers.
Looking at the Return On Invested Capital, with a value of 15.05%, BIO belongs to the top of the industry, outperforming 94.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.97% | ||
| ROE | 35.86% | ||
| ROIC | 15.05% |
ROA(3y)0.14%
ROA(5y)-0.57%
ROE(3y)-0.13%
ROE(5y)-1.74%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BIO's Profit Margin of 23.75% is amongst the best of the industry. BIO outperforms 93.06% of its industry peers.
BIO's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 28.40%, BIO belongs to the best of the industry, outperforming 91.67% of the companies in the same industry.
In the last couple of years the Operating Margin of BIO has grown nicely.
BIO has a Gross Margin of 46.62%. This is comparable to the rest of the industry: BIO outperforms 58.33% of its industry peers.
BIO's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.4% | ||
| PM (TTM) | 23.75% | ||
| GM | 46.62% |
OM growth 3YN/A
OM growth 5Y40.83%
PM growth 3YN/A
PM growth 5Y-16.36%
GM growth 3Y15.07%
GM growth 5Y3.99%
2. Health
2.1 Basic Checks
BIO has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for BIO remains at a similar level compared to 1 year ago.
Compared to 5 years ago, BIO has more shares outstanding
The debt/assets ratio for BIO has been reduced compared to a year ago.
2.2 Solvency
BIO has an Altman-Z score of 2.96. This is not the best score and indicates that BIO is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of BIO (2.96) is better than 79.17% of its industry peers.
The Debt to FCF ratio of BIO is 5.23, which is a neutral value as it means it would take BIO, 5.23 years of fcf income to pay off all of its debts.
BIO has a Debt to FCF ratio of 5.23. This is amongst the best in the industry. BIO outperforms 81.94% of its industry peers.
BIO has a Debt/Equity ratio of 0.80. This is a neutral value indicating BIO is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.80, BIO perfoms like the industry average, outperforming 43.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.8 | ||
| Debt/FCF | 5.23 | ||
| Altman-Z | 2.96 |
ROIC/WACC2.26
WACC6.65%
2.3 Liquidity
BIO has a Current Ratio of 2.45. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
BIO's Current ratio of 2.45 is in line compared to the rest of the industry. BIO outperforms 52.78% of its industry peers.
A Quick Ratio of 0.88 indicates that BIO may have some problems paying its short term obligations.
With a Quick ratio value of 0.88, BIO is not doing good in the industry: 69.44% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.45 | ||
| Quick Ratio | 0.88 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 32.71% over the past year.
BIO shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -6.87% yearly.
BIO shows a decrease in Revenue. In the last year, the revenue decreased by -8.51%.
BIO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.33% yearly.
EPS 1Y (TTM)32.71%
EPS 3YN/A
EPS 5Y-6.87%
EPS Q2Q%-108.65%
Revenue 1Y (TTM)-8.51%
Revenue growth 3Y12.24%
Revenue growth 5Y11.33%
Sales Q2Q%-40.39%
3.2 Future
BIO is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -31.29% yearly.
Based on estimates for the next years, BIO will show a small growth in Revenue. The Revenue will grow by 2.49% on average per year.
EPS Next Y-103.15%
EPS Next 2Y-31.29%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-6.17%
Revenue Next 2Y2.49%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 23.98 indicates a rather expensive valuation of BIO.
86.11% of the companies in the same industry are more expensive than BIO, based on the Price/Earnings ratio.
BIO's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 29.35.
The Price/Forward Earnings ratio is 27.06, which means the current valuation is very expensive for BIO.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BIO indicates a rather cheap valuation: BIO is cheaper than 80.56% of the companies listed in the same industry.
BIO is valuated rather expensively when we compare the Price/Forward Earnings ratio to 22.10, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.98 | ||
| Fwd PE | 27.06 |
4.2 Price Multiples
90.28% of the companies in the same industry are more expensive than BIO, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, BIO is valued cheaper than 90.28% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.6 | ||
| EV/EBITDA | 8.07 |
4.3 Compensation for Growth
BIO has a very decent profitability rating, which may justify a higher PE ratio.
A cheap valuation may be justified as BIO's earnings are expected to decrease with -31.29% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-31.29%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for BIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:BIO (3/6/2025, 7:00:00 PM)
41
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.21%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.62B
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.98 | ||
| Fwd PE | 27.06 | ||
| P/S | 2.01 | ||
| P/FCF | 13.6 | ||
| P/OCF | 13.6 | ||
| P/B | 3.03 | ||
| P/tB | 3.11 | ||
| EV/EBITDA | 8.07 |
EPS(TTM)1.71
EY4.17%
EPS(NY)1.52
Fwd EY3.7%
FCF(TTM)3.01
FCFY7.35%
OCF(TTM)3.01
OCFY7.35%
SpS20.45
BVpS13.54
TBVpS13.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.97% | ||
| ROE | 35.86% | ||
| ROCE | 21.38% | ||
| ROIC | 15.05% | ||
| ROICexc | 16.34% | ||
| ROICexgc | 16.59% | ||
| OM | 28.4% | ||
| PM (TTM) | 23.75% | ||
| GM | 46.62% | ||
| FCFM | 14.74% |
ROA(3y)0.14%
ROA(5y)-0.57%
ROE(3y)-0.13%
ROE(5y)-1.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y50.28%
ROICexc growth 3YN/A
ROICexc growth 5Y50.45%
OM growth 3YN/A
OM growth 5Y40.83%
PM growth 3YN/A
PM growth 5Y-16.36%
GM growth 3Y15.07%
GM growth 5Y3.99%
F-Score6
Asset Turnover0.59
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.8 | ||
| Debt/FCF | 5.23 | ||
| Debt/EBITDA | 1.62 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 7.14 | ||
| Cash Conversion | 44.9% | ||
| Profit Quality | 62.07% | ||
| Current Ratio | 2.45 | ||
| Quick Ratio | 0.88 | ||
| Altman-Z | 2.96 |
F-Score6
WACC6.65%
ROIC/WACC2.26
Cap/Depr(3y)77.8%
Cap/Depr(5y)86.44%
Cap/Sales(3y)4.7%
Cap/Sales(5y)5.56%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.71%
EPS 3YN/A
EPS 5Y-6.87%
EPS Q2Q%-108.65%
EPS Next Y-103.15%
EPS Next 2Y-31.29%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-8.51%
Revenue growth 3Y12.24%
Revenue growth 5Y11.33%
Sales Q2Q%-40.39%
Revenue Next Year-6.17%
Revenue Next 2Y2.49%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y1037.96%
EBIT growth 3YN/A
EBIT growth 5Y56.78%
EBIT Next Year-53.82%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y145.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y145.47%
OCF growth 3YN/A
OCF growth 5YN/A